Sionna Therapeutics, Inc. cash flow statement SION

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, Sionna Therapeutics, Inc. used $66.3 million of cash from operations. It spent $377,000 on capital expenditures. Free cash flow was negative, at -$66.7 million.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
Operating
Depreciation and amortization
1
1
Stock-based compensation
21
12
Operating cash flow
-76
-66
Investing
Capital expenditures
0
0
Investing cash flow
92
-119
Financing
Financing cash flow
6
206
Change in cash
Net change in cash
22
21
Free cash flow
-76
-67
Per share
Free cash flow per share
-1.70
-1.67
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
SION (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Waltham, MA
SEC filer status
, Emerging growth company
SEC CIK
2036042

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.